H.C. Wainwright launched coverage of OmniAb (NASDAQ:OABI) with a “buy” rating and a price target of $11. The stock closed at $3.88 on Feb. 10. At its core, OmniAb is an antibody discovery, optimization, and licensing...
Stifel launched coverage of OmniAb (NASDAQ:OABI) with a “buy” rating and $12 price target. The stock closed at $2.61 on Nov. 25. Analyst Stephen Willey writes that OmniAb represents the construction of a high-throughput...